Bladder cancer vaccine - ID Biomedical
Alternative Names: PACISLatest Information Update: 24 Oct 2021
At a glance
- Originator Bio Chem Pharma
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Bladder cancer
Most Recent Events
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 21 Sep 2004 Shire Biologics has been acquired and merged into ID Biomedical Corporation
- 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group